Irreversible HER2 inhibitors overcome resistance to the RSL3 ferroptosis inducer in non-HER2 amplified luminal breast cancer.

Park, Soon Young; Jeong, Kang Jin; Poire, Alfonso; Zhang, Dong; Tsang, Yiu Huen; Blucher, Aurora S; Mills, Gordon B

Park, Soon Young; Jeong, Kang Jin; Poire, Alfonso; Zhang, Dong; Tsang, Yiu Huen; Blucher, Aurora S; Mills, Gordon B.

Afiliação

Park SY; Division of Oncologic Sciences, Knight Cancer Institute, Oregon Health Sciences University, Portland, OR, USA. parkso@ohsu.edu.
Jeong KJ; Division of Oncologic Sciences, Knight Cancer Institute, Oregon Health Sciences University, Portland, OR, USA.
Poire A; Division of Oncologic Sciences, Knight Cancer Institute, Oregon Health Sciences University, Portland, OR, USA.
Zhang D; Division of Oncologic Sciences, Knight Cancer Institute, Oregon Health Sciences University, Portland, OR, USA.
Tsang YH; Division of Oncologic Sciences, Knight Cancer Institute, Oregon Health Sciences University, Portland, OR, USA.
Blucher AS; Division of Oncologic Sciences, Knight Cancer Institute, Oregon Health Sciences University, Portland, OR, USA.
Mills GB; Division of Oncologic Sciences, Knight Cancer Institute, Oregon Health Sciences University, Portland, OR, USA.

Cell Death Dis ; 14(8): 532, 2023 08 18.

Article em En | MEDLINE | ID: mdl-37596261

Assuntos

Ferroptose; Neoplasias; Humanos; Apoptose; Peroxidação de Lipídeos; Ferro; Células MCF-7; Proteínas de Membrana Transportadoras

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ferroptose / Neoplasias Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google